AR094904A1 - Análogos de insulina y su uso - Google Patents

Análogos de insulina y su uso

Info

Publication number
AR094904A1
AR094904A1 ARP140100614A ARP140100614A AR094904A1 AR 094904 A1 AR094904 A1 AR 094904A1 AR P140100614 A ARP140100614 A AR P140100614A AR P140100614 A ARP140100614 A AR P140100614A AR 094904 A1 AR094904 A1 AR 094904A1
Authority
AR
Argentina
Prior art keywords
insulin
conjugate
insulin analogs
reduced
prepares
Prior art date
Application number
ARP140100614A
Other languages
English (en)
Inventor
Young Choi In
Ho Huh Yong
Youn Hwang Sang
Young Kim Jin
Hee Hong Sung
Youb Jung Sung
Chang Kwon Se
Jin Kim Dae
Uk Kim Hyun
Hyun Jang Myung
Su Kim Seung
Original Assignee
Hanmi Pharm Ind Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hanmi Pharm Ind Co Ltd filed Critical Hanmi Pharm Ind Co Ltd
Publication of AR094904A1 publication Critical patent/AR094904A1/es

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6849Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a receptor, a cell surface antigen or a cell surface determinant
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/16Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22Hormones
    • A61K38/28Insulins
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6801Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
    • A61K47/6803Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
    • A61K47/6811Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being a protein or peptide, e.g. transferrin or bleomycin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6889Conjugates wherein the antibody being the modifying agent and wherein the linker, binder or spacer confers particular properties to the conjugates, e.g. peptidic enzyme-labile linkers or acid-labile linkers, providing for an acid-labile immuno conjugate wherein the drug may be released from its antibody conjugated part in an acidic, e.g. tumoural or environment
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/08Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575Hormones
    • C07K14/62Insulins
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K17/00Carrier-bound or immobilised peptides; Preparation thereof
    • C07K17/02Peptides being immobilised on, or in, an organic carrier
    • C07K17/08Peptides being immobilised on, or in, an organic carrier the carrier being a synthetic polymer
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2319/00Fusion polypeptide
    • C07K2319/30Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Diabetes (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Endocrinology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Toxicology (AREA)
  • Cell Biology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Emergency Medicine (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)

Abstract

La presente se refiere a un análogo de insulina que tiene un titulo de insulina reducido y una afinidad de unión del receptor de insulina reducida en comparación con la forma natural con el fin de incrementar la vida media de la insulina en sangre, un conjugado que se prepara enlazando el análogo de insulina y un portador, una formulación de acción prolongada que incluye el conjugado, y un procedimiento para preparar el conjugado.
ARP140100614A 2013-02-26 2014-02-26 Análogos de insulina y su uso AR094904A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
KR20130020703 2013-02-26

Publications (1)

Publication Number Publication Date
AR094904A1 true AR094904A1 (es) 2015-09-09

Family

ID=51428525

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP140100614A AR094904A1 (es) 2013-02-26 2014-02-26 Análogos de insulina y su uso

Country Status (22)

Country Link
US (1) US10046061B2 (es)
EP (1) EP2963055B1 (es)
JP (1) JP6465817B2 (es)
KR (1) KR102185311B1 (es)
CN (1) CN105229025B (es)
AR (1) AR094904A1 (es)
AU (1) AU2014221534B2 (es)
BR (1) BR112015018828B1 (es)
CA (1) CA2899418C (es)
ES (1) ES2738676T3 (es)
HK (1) HK1217202A1 (es)
IL (1) IL240714B (es)
MX (1) MX361083B (es)
NZ (1) NZ710564A (es)
PH (1) PH12015501815A1 (es)
PT (1) PT2963055T (es)
RU (1) RU2677800C2 (es)
SA (1) SA515360887B1 (es)
SG (1) SG11201505615PA (es)
TR (1) TR201910929T4 (es)
WO (1) WO2014133327A1 (es)
ZA (1) ZA201507105B (es)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20130049671A (ko) 2011-11-04 2013-05-14 한미사이언스 주식회사 생리활성 폴리펩타이드 결합체 제조 방법
AR090281A1 (es) * 2012-03-08 2014-10-29 Hanmi Science Co Ltd Proceso mejorado para la preparacion de un complejo polipeptidico fisiologicamente activo
JP2018508504A (ja) * 2015-02-17 2018-03-29 ハンミ ファーマシューティカル カンパニー リミテッド 持続型インスリンまたはインスリンアナログ結合体
AR105616A1 (es) 2015-05-07 2017-10-25 Lilly Co Eli Proteínas de fusión
UY36870A (es) * 2015-08-28 2017-03-31 Hanmi Pharm Ind Co Ltd Análogos de insulina novedosos
BR112019005637A2 (pt) 2016-09-23 2019-07-30 Hanmi Pharm Ind Co Ltd análogos da insulina com afinidade reduzida para o receptor de insulina e seu uso
CA3054899A1 (en) 2017-03-23 2018-09-27 Hanmi Pharm. Co., Ltd. Insulin analog complex with reduced affinity for insulin receptor and use thereof
KR20190038456A (ko) * 2017-09-29 2019-04-08 한미약품 주식회사 효력이 향상된 지속성 단백질 결합체

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6096871A (en) 1995-04-14 2000-08-01 Genentech, Inc. Polypeptides altered to contain an epitope from the Fc region of an IgG molecule for increased half-life
EP0904107B1 (en) 1996-03-18 2004-10-20 Board Of Regents, The University Of Texas System Immunoglobin-like domains with increased half lives
KR101135244B1 (ko) * 2007-11-29 2012-04-24 한미사이언스 주식회사 인슐린 분비 펩타이드 결합체를 포함하는 비만 관련질환 치료용 조성물
US20090285780A1 (en) * 2006-05-24 2009-11-19 Chyi Lee Peg linker compounds and biologically active conjugates thereof
AU2010225523B2 (en) 2009-03-20 2012-05-24 Hanmi Science Co., Ltd. Method for preparing a site-specific physiologically active polypeptide conjugate
AR081066A1 (es) 2010-04-02 2012-06-06 Hanmi Holdings Co Ltd Conjugado de insulina donde se usa un fragmento de inmunoglobulina
KR101330868B1 (ko) * 2010-06-08 2013-11-18 한미사이언스 주식회사 면역글로불린 단편을 이용한 인슐린 유도체 약물 결합체
CA2802485C (en) * 2010-06-16 2019-09-17 Indiana University Research And Technology Corporation Single chain insulin agonists exhibiting high activity at the insulin receptor
CN103533952B (zh) 2011-03-15 2017-02-15 诺沃—诺迪斯克有限公司 包含半胱氨酸置换的人胰岛素类似物和衍生物
CN102675452B (zh) 2011-03-17 2015-09-16 重庆富进生物医药有限公司 具持续降血糖和受体高结合的人胰岛素及类似物的偶联物
TWI565714B (zh) * 2011-06-02 2017-01-11 韓美科學股份有限公司 非肽基聚合物-胰島素集合體及其製造方法
UA113626C2 (xx) * 2011-06-02 2017-02-27 Композиція для лікування діабету, що містить кон'югат інсуліну тривалої дії та кон'югат інсулінотропного пептиду тривалої дії

Also Published As

Publication number Publication date
ES2738676T3 (es) 2020-01-24
EP2963055A1 (en) 2016-01-06
NZ710564A (en) 2020-06-26
CN105229025B (zh) 2019-11-19
SA515360887B1 (ar) 2018-10-25
TR201910929T4 (tr) 2019-08-21
CA2899418A1 (en) 2014-09-04
PH12015501815B1 (en) 2015-12-07
JP6465817B2 (ja) 2019-02-06
PT2963055T (pt) 2019-07-25
RU2015133462A (ru) 2017-03-31
AU2014221534A1 (en) 2015-08-20
EP2963055B1 (en) 2019-05-15
MX2015009799A (es) 2015-10-29
BR112015018828B1 (pt) 2024-01-30
ZA201507105B (en) 2017-11-29
WO2014133327A1 (ko) 2014-09-04
CA2899418C (en) 2022-05-03
EP2963055A4 (en) 2016-10-19
AU2014221534B2 (en) 2018-06-28
PH12015501815A1 (en) 2015-12-07
MX361083B (es) 2018-11-27
US20160000931A1 (en) 2016-01-07
KR102185311B1 (ko) 2020-12-01
SG11201505615PA (en) 2015-09-29
KR20140106455A (ko) 2014-09-03
RU2677800C2 (ru) 2019-01-21
HK1217202A1 (zh) 2016-12-30
JP2016510004A (ja) 2016-04-04
IL240714B (en) 2020-05-31
US10046061B2 (en) 2018-08-14
CN105229025A (zh) 2016-01-06
BR112015018828A2 (es) 2017-08-15
IL240714A0 (en) 2015-10-29

Similar Documents

Publication Publication Date Title
PE20151409A1 (es) Analogo de insulina novedoso y su uso
AR094904A1 (es) Análogos de insulina y su uso
CL2023001911A1 (es) Derivado de glucagón y una composición que comprende un conjugado de acción prolongada del mismo
CL2019000334A1 (es) Nuevos conjugados de anticuerpo y usos de los mismos (divisional solicitud 201502357)
CL2016000468A1 (es) Conjugados anti-dll3 (ligando3 tipo delta) manipulados y métodos de uso.
ECSP16068524A (es) Insulina de acción prolongada y uso de la misma
CL2017003356A1 (es) Moduladores cot y métodos de uso de los mismos
CY1123953T1 (el) Καθυστερημενης απελευθερωσης συνθεσεις λινακλοτιδης
PE20171376A1 (es) Nuevos indazoles sustituidos, procedimientos para su preparacion, preparaciones farmaceuticas que los contienen, asi como su uso para la preparacion de medicamentos
AR102712A1 (es) Agonistas parciales del receptor de insulina
GT201400297A (es) Nuevos derivados tienopirimidina, un proceso para su preparación y composiciones farmacéuticas que los contienen
EA201991715A1 (ru) Композиции, содержащие антитело к pdl1
EA201691911A1 (ru) Быстродействующие композиции инсулина
PE20160870A1 (es) Anticuerpos anti-claudina novedosos y metodos de uso
ES2681973T3 (es) Respuesta antitumoral contra autoepítopos modificados
AR101455A1 (es) Molécula portadora
AR091908A1 (es) COMPLEJO CRISTALINO DE 1-CIANO-2-(4-CICLOPROPIL-BENCIL)-4-(b-D-GLUCOPIRANOS-1-IL)-BENCENO, METODOS PARA SU PREPARACION Y SU USO PARA PREPARAR MEDICAMENTOS
BR112016029860A2 (pt) conjugados de anticorpo antirreceptor alfa de folato (fra)-fármaco e métodos de uso dos mesmos
BR112016008576A2 (pt) Formulações aquosas estáveis de anticorpos e forma farmacêutica de dosagem unitária
CL2015002724A1 (es) Métodos para tratar la enfermedad de crohn utilizando un anticuerpo anti-il23
BR112015030356A2 (pt) métodos de tratamento de uma taupatia
BR112016008736A2 (pt) formulação estável de insulina glulisina
BR112015030268A2 (pt) composição farmacêutica, recipiente, kit, e, método para a preparação de uma composição
CL2012003458A1 (es) Vector que comprende un polipeptido antigénico de campylobacter; composicion farmacéutica que comprende dicho vector; uso del vector para mejorar respuesta inmune del sujeto al polipéptido antigénico.
CO7151478A2 (es) Formulaciones estabilizadas que contienen anticuerpos anti-dll4